Condition: Colorectal Cancer · Cholangiocarcinoma · Appendiceal Adenocarcinoma · Sponsor: Apollo Therapeutics Ltd
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
This description comes directly from the study's public registry record.
Apollo Therapeutics · 781-479-2267 · AP10@apollotx.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Active Not Recruiting |
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine, California, United States | Active Not Recruiting |
| Florida Cancer Specialists & Research Institute | Sarasota, Florida, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Duke Cancer Institute | Durham, North Carolina, United States | Recruiting |
| Carolina BioOncology Institute | Huntersville, North Carolina, United States | Recruiting |
| Medical University of South Carolina | Charleston, South Carolina, United States | Recruiting |
| Mary Crowley Cancer Research | Dallas, Texas, United States | Recruiting |
| NEXT Oncology- San Antonio | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06399757